MoonLake Immunotherapeutics Reports Third-Quarter Net Loss of $79.5M
The clinical-stage company reported a net loss attributable to controlling shareholders of $79.5 million, compared with $69.7 million a year earlier, and no product sales revenue. Basic and diluted loss per share narrowed to $0.93 from…
MoonLake Immunotherapeutics reported a net loss attributable to controlling shareholders of $79.5M for the third quarter of 2026, compared with $69.7M a year earlier, as the clinical-stage company continued to report no product sales revenue. Basic and diluted loss per share narrowed to $0.93 from…